E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Great Debates and Updates in Breast Cancer

Register


Great Debates & Updates in Breast Cancer

June 19-20, 2009

San Francisco, California, USA

Palace Hotel

 

Continuing Medical Education

ACCME

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex designates this educational activity for a maximum 9.75 of AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Who Should Attend

This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with breast cancer.

 

Objectives

After successful completion of this course, attendees should be able to:

  • Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making, while identifying the latest and most important prognostic and predictive factors in breast cancer
  • Discuss recent advancements in surgery and radiation therapy for the treatment of breast cancer
  • Review emerging research findings concerning breast cancer risk and chemoprevention
  • Comment on the latest translational research developments improving our understanding of breast tumor biology
  • Summarize current therapeutic options for the management of patients with early-stage or locally advanced breast cancer
  • Compare and contrast the most appropriate treatment regimens utilizing neoadjuvant and adjuvant therapies
  • Review current and emerging research in the pathogenesis and therapies for triple-negative breast cancers
  • Describe the biologic rationale for HER2-targeted therapies, and discuss recent clinical trial data  evaluating novel HER2-directed agents in early-stage and advanced disease
  • Compare endocrine treatment options, including timing and sequencing of aromatase inhibitors in adjuvant regimens and the integration of bisphosphonates, for patients with hormone receptor-positive breast cancer
  • List the most promising current and future strategies for the management of metastatic breast cancer
  • Interpret and integrate recent clinical trial data into improved patient management strategies

 

 

 

Helen Chew, MD
University of California Davis Cancer
Sacramento, California

Mary E. Cianfrocca, DO
Northwestern University
Chicago, Illinois

Anthony Elias, MD
University of Colorado
Denver School of Medicine
Aurora, Colorado

Julie Gralow, MD
University of Washington & Fred Hutchinson Cancer Research Institute
Seattle, Washington

Dennis R. Holmes, MD, FACP
University of Southern California
Los Angeles, California

 

Virginia Kaklamani, MD
Northwestern University
Chicago, Illinois

Michelle E. Melisko, MD
UCSF Comprehensive Cancer Center,
University of California San Francisco
San Francisco, California

Lori J. Pierce, MD
University of Michigan
Ann Arbor, Michigan

Lawrence Solin, MD, FACR, FASTRO
Albert Einstein Medical Center
Philadelphia, Pennsylvania

 

Friday, June 19, 2009

9:00 am
Welcome and introduction
William J. Gradishar, MD, FACP and Hope Rugo, MD

9:10 am
Debate: Should MRI be performed prior to surgery on everyone with a diagnosis of early stage breast cancer?

9:40 am
Debate: Should patients with low-risk node-positive disease have gene profiling performed to help with decision making?

10:10 am
Debate: Should the SLN procedure be performed before or after administration of neoadjuvant chemotherapy?

10:40 am
Discussion

10:50 am
Break

11:10 am
Optimal strategies for the treatment of metastatic triple-negative breast cancer

11:40 am
Clinical applicability of available genomic profiling techniques

12:10 pm
Debate: Should all patients receiving tamoxifen have CYP2D6 genotyping performed?

12:40 pm
Discussion

12:50 pm
Lunch

1:50 pm
Debate: All patients with untreated metastatic ER+/HER2+ breast cancer should receive an anti-HER2 agent in addition to hormone therapy?

2:20 pm
Debate: 68 year old with Stage II, ER +, lymph node (+) breast cancer with recent history of osteoporotic spine fractures now on calcium, Vitamin D, and a bisphosphonate. What adjuvant hormone therapy is most appropriate?

2:50 pm
Debate: A 42-year old patient with triple-negative breast cancer receives neoadjuvant anthracycline/taxane-based chemotherapy, but significant residual disease remains after therapy. Should more systemic chemotherapy be administered?

3:20 pm
Discussion

3:30 pm
Adjourn

 

 

 

Saturday, June 20, 2009

9:00 am
Welcome and introduction
William J. Gradishar, MD, FACP and Hope Rugo, MD

9:10 am
Debate: All patients with small T1a, T1b HER2-positive (ER-/PR-) disease should receive anti-HER2 therapy in adjuvant setting?

9:40 am
Clinical updates in translational science for breast cancer: What’s on the horizon?

10:10 am
Debate: Is short course radiotherapy as safe and effective as conventional fractionation schedules?

10:40 am
Discussion

10:50 am
Break

11:10 am
Debate: Should tumor markers be utilized in the routine follow-up of patients with breast cancer?

11:40 am
Cognitive impairment in the breast cancer patient: Fact or fiction?
Hope Rugo, MD

12:00 pm
Debate: Should anthracyclines be omitted from adjuvant chemotherapy regimens for patients with HER2-negative invasive breast cancer?

12:30 pm
Discussion

12:40 pm
Lunch

1:40 pm
Management of brain metastases in ER+ and ER- breast cancer

2:10 pm
Novel targeted therapies in clinical trials

2:40 pm
Debate: What is the optimal management strategy of patients whose disease progresses while on trastuzumab?

3:10 pm
Discussion

3:20 pm
Adjourn


 

 

Registration Fees

Physicians...........................................$150

Nurses, Fellows, Residents..................$75

Pharmaceutical Industry......................$175

 

Registration Procedure

To Register:
You may register online by June 11, 2009 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment:
To pre-register, registration and payment must be received no later than June 11, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

 

Hotel Accommodations

Palace Hotel
2 New Montgomery Street
San Francisco, CA 94105
Phone: +1 (415) 512 1111
Fax: +1 (415) 543 0671
http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0812183327&key=1F678

 

Built in 1875 to celebrate the West Coast boom, the Palace Hotel, San Francisco is one of San Francisco’s most treasured landmarks. The hotel is located just steps away from Union Square, Chinatown, the Financial District and the Moscone Convention Center.

For the convenience of attendees, a limited number of rooms have been reserved until May 19, 2009 at a discounted rate of $225 single/double occupancy, plus tax, currently at 14.065%. This rate is not guaranteed outside the conference dates or after May 19, 2009.

To reserve your room, please contact the Palace Hotel reservations department at +1 (415) 512 1111 or visit the hotel’s website at http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0812183327&key=1F678. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Breast Cancer group. Reservation requests received after May 19, 2009 may not be guaranteed the group rate.

 

 

Hotel Accommodations

Palace Hotel
2 New Montgomery Street
San Francisco, CA 94105
Phone: +1 (415) 512 1111
Fax: +1 (415) 543 0671
http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0812183327&key=1F678

 

Built in 1875 to celebrate the West Coast boom, the Palace Hotel, San Francisco is one of San Francisco’s most treasured landmarks. The hotel is located just steps away from Union Square, Chinatown, the Financial District and the Moscone Convention Center.

For the convenience of attendees, a limited number of rooms have been reserved until May 19, 2009 at a discounted rate of $225 single/double occupancy, plus tax, currently at 14.065%. This rate is not guaranteed outside the conference dates or after May 19, 2009.

To reserve your room, please contact the Palace Hotel reservations department at +1 (415) 512 1111 or visit the hotel’s website at http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0812183327&key=1F678. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Breast Cancer group. Reservation requests received after May 19, 2009 may not be guaranteed the group rate.

 

 

Dear Colleague,

It is with great pleasure and enthusiasm that we invite you to Great Debates and Updates in Breast Cancer, June 19-20, 2009, in San Francisco, California. This conference promises to be an exciting two-day interactive and educational experience for attendees from all breast cancer related disciplines. The meeting will be a world class medical education forum for the exchange of critical information in the field of breast cancer. It will feature didactic presentations and debates, in which recognized thought leaders discuss some of the most challenging topics in breast cancer. These leading experts will provide you with a thorough analysis of current as well as new areas of research and emerging data. Especially highlighted will be the bench to bedside application for your community practice. We hope you will be able to join us in San Francisco for what is sure to be a rewarding experience!

Sincerely,

William Gradishar, MD, FACP

Hope Rugo, MD

 

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

 

Conference Location and Registration

Palace Hotel
2 New Montgomery Street
San Francisco, CA 94105
Phone: +1 (415) 512 1111
Fax: +1 (415) 543 0671

 

The Registration and Information Desk will be staffed:

Friday, June 19, 2009
7:00 am – 4:30 pm

Saturday, June 20, 2009
7:00 am – 4:30 pm

 

 

 



PDF Announcement

 

Chairs:

William Gradishar, MD, FACP
Northwestern University Medical School
Chicago, Illinois

Hope Rugo, MD
University of California San Francisco
San Francisco, California

 

Course Director:

Christy Russell, MD
University of Southern California
Keck School of Medicine
Los Angeles, California

 

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

 

Cancellation:

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than June 11, 2009. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after June 11, 2009. Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

 

Quotes from past participants:

“Excellent conference. The speakers were well informed and prepared”

“Debate forum was great”

“Physicians absent from this conference are missing a massive amount of new information and not getting the benefit of the superb faculty”

The following companies have provided an education grant in support of this conference:

Gold:

Genentech BioOncology

BMS

Silver:

Novartis

Corporate:

Genomic Health

Wyeth

 

Several options are available to companies interested in supporting this Conference. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

 

The following companies are exhibitors at this conference:

Agendia